Stock News

FDA cleared the weekly basal insulin for adults with type 2 diabetes on Sept. 24; Lilly expects the U.S. pen in the coming months.

An unnamed AI lab committed to enter a separate ten-year Barber Lake lease after Fluidstack's term; first rent commencement is expected in the fourth quarter of 2026.

Hole TAK-26-16 includes 229 grams per tonne gold over 0.65 metre, with results from four Phase III holes pending.

The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

SIDEX and NQ Mining Investment lead the flow-through sale, priced at C$0.145 a share and expected to close about Sept. 29.

The Sept. 25 weekly update lists 288.1 BTC mined and zero net coins added; Friday's Nasdaq close predates the post.

COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.

The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.

Its July placement issued 35.98 million shares and matching warrants, while the latest notice disclosed $334,577 in finder fees.

Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.

In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.

The Swiss cybersecurity group expects Oct. 2 to be the last session for its existing ADSs and Class B shares before a planned WISeQey listing.

The Swedish developer says the deal could bring up to €1.165B, but its published terms do not separate the upfront payment from later milestones.

The partners cited FDA discussions over Phase 2 evidence and kept a randomized Phase 3 lung cancer trial enrolling.

The US$3.65 units carry half a warrant each, and Goldgroup has not assigned the proceeds to specific projects.

The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.

The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.

Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.

Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.

A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.

It counted 180 new customer contracts through Sept. 23 but gave no schedule for recognizing their value as revenue.

Adjusted EPS beat BlackBerry's June outlook, while the company forecast a sharp licensing revenue decline in the next quarter.

Both doses passed a vision noninferiority test against ranibizumab; higher rates of retinal complications await detail.

The new Phase 3 study shifts its primary measure to lung function after an earlier miss, but aTyr says it needs more money to run it.

The company gave no sale proceeds or new cash balance, leaving its June 30 cash of US$21.0 million as the latest figure disclosed in the releases.

The FDA will decide whether to file the application for review after PROSERA's walking-distance gain missed its preset statistical cutoff.

Elegancia will deliver the Qatari facility in two phases, but the companies gave no power rating or completion date.

The first US$7 million draw needs a shareholder vote, while later tranches depend on U.S. listing steps and the first Phase 3 site.

The Nasdaq-listed miner says it has completed Sarfartoq fieldwork and expects the financing to fund its 2027 milestones.

The TIBA test joins two existing checks on new commercial lots as Mesoblast scales U.S. sales of its pediatric cell therapy.

The company priced up to nine million flow-through shares at C$0.25, with proceeds earmarked for its 2026 Loki exploration program.

Aurora cites missing pro forma financials, a French-language notice and the mandatory 105-day deposit period in its ASC application.

The proposed deal gives Elmet a Masan board seat and starts tungsten supply agreements once the equity purchase closes.

The acquired portfolio spans 862 square kilometres in central Saudi Arabia, with historic gold intercepts at Jabal Jumaymah and Wadi Jarir.

Three of six initial holes have assays as drilling tests the newly leased ground between two mineralized areas at Slumber.

Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

A Sept. 16 agreement covers 32 servers from Compal; Quanome targets a fourth-quarter opening but has disclosed no cloud customer.

The 103.5 million new shares fund a 42,000-metre drill program and work toward a 2027 study of the Misisi gold project.

Ricks gave no period or patient count for the estimate as Lilly broke ground on its US$6.5 billion Houston ingredients plant.